Objective:To investigate immunotherapy effects and mechanism of BCG and recombinant BCG(rBCG)with c-di-AMP as adjuvant on melanoma in mice model.Methods:Melanoma mice model was established by B16F10 cell subcutaneous injec-tion in groin,and treated with 1×106 CFU of BCG and rBCG by adjacent injection of subcutaneous tumor for 3 times,respectively.Survival of melanotic mice,tumor growth and metastasis were observed.Tumor tissues of mice were isolated to prepare cell suspen-sion,and proportion of immune cells were detected by flow cytometry.Transcriptional levels of immune-related genes in tumor tissues were detected by qRT-PCR.Results:Both BCG and rBCG immunotherapy could significantly inhibit growth in melanoma mice and prolong survival time of mice.rBCG showed better inhibition on metastasis than BCG.Both strains significantly reduced proportion of M2-type macrophages and myeloid-derived suppressor cell associated with tumor growth and metastasis.Both two strains promoted infiltration of lymphocytes in tumor tissues,and rBCG significantly increased proportion of B cells in tumor.BCG immunotherapy upregulated transcription levels of metastasis-related cytokines,while rBCG therapy had no effects on transcriptions of these genes.Conclusion:Both BCG and rBCG have immunotherapeutic effects on melanotic mice,and rBCG with c-di-AMP as adjuvant shows better inhibition on tumor metastasis than BCG,which mechanism was related to regulation of immune response in tumor tissues.

The development of 5G remote robot-assisted gastrointestinal surgery is an important breakthrough in remote surgery in the field of four-level surgery. This paper will review the development history of 5G remote robot assisted gastrointestinal surgery, and share the Gansu province people′s hospital in 5G remote robot assisted gastrointestinal surgery about preoperative preparation, network and equipment connection,“3+2” Trocar layout, safety emergency treatment mechanism of exploratory experience, for 5G remote robot assisted gastrointestinal surgery, and the status and prospect of 5G remote robot assisted gastrointestinal surgery.

Oral squamous cell carcinoma (OSCC) is a malignant tumor that seriously threatens human health. Its typical biological characteristics include strong local invasiveness, high lymph node metastasis rate, and high recurrence rate after treatment. Hepatocyte growth factor (HGF), cellular-mesenchymal to epithelial transition factor (c-Met), and the HGF/c-Met signaling pathway are involved in the regulation of the occurrence and development of OSCC. HGF and c-Met proteins are overexpressed in OSCC, and multiple studies have suggested that they are significantly associated with the malignant characteristics of tumors and poor prognosis. Furthermore, the abnormal activation of the HGF/c-Met signaling pathway (driven by HGF-dependent autocrine/paracrine or non-dependent mechanisms such as MET gene mutations, amplification, fusion, and protein overexpression) can synergistically promote tumor cell invasion, metastasis, and angiogenesis by activating downstream signaling pathways. However, HGF/c-Met can also mediate immune escape by promoting lactate secretion increase, inducing programmed death ligand 1 (PD-L1) expression upregulation, activating and expanding myeloid-derived suppressor cells, and promoting the proliferation of regulatory T cells (Tregs). In addition, the crosstalk between the HGF/c-Met signaling pathway and key pathways such as phosphatidylinositide 3-kinases (PI3K)/protein kinase B (AKT), epidermal growth factor receptor (EGFR), Janus kinase (JAK)/signal transducer and activator of transcription (STAT3), and non-coding RNAs can also promote tumor progression. Currently, three types of targeted drugs have been developed targeting the HGF/c-Met pathway: HGF monoclonal antibody, c-Met monoclonal antibody, and tyrosine kinase inhibitors. Some of these drugs have entered clinical trials. However, the emergence of drug resistance during treatment, especially the bidirectional compensatory activation of alternative signaling pathways such as EGFR, has become a major challenge in clinical practice. This article aims to provide an in-depth analysis of the mechanism of action of the HGF/c-Met pathway in OSCC and its interaction with other pathways, and to review the current research status of existing therapeutic drugs. The aim is to provide an important theoretical basis for developing more effective combined treatment strategies and achieving individualized precise treatment, ultimately improving the clinical prognosis and quality of life of patients.

Objective:To compare the efficacies of endovascular therapy (EVT) and standard medical therapy in acute ischemic stroke (AIS) patients aged ≥85 years, and analyze the independent influencing factors for poor prognosis of AIS patients after EVT.Methods:Sixty-nine AIS patients aged ≥85 years admitted to Department of Neurology, Xi'an Third Hospital from January 2018 to April 2024, including 40 accepted EVT and 28 accepted standard medicinal therapy, were enrolled. Modified Rankin scale (mRS) was used to evaluate the prognosis of the patients 90 days after onset. General data, prognosis and complications between the EVT group and standard medical therapy group were compared. General data, treatment processes and complications between patients with good prognosis and poor prognosis in the EVT group were compared. Multivariate Logistic regression was used to analyze the independent influencing factors for poor prognosis in AIS patients after EVT.Results:Compared with the standard medical therapy, the EVT group had significantly lower NIHSS score at discharge, greater improvement in NIHSS score (NIHSS score at admission-NIHSS score at discharge), lower mRS score 90 days after onset, higher good prognosis rate, lower mortality rate within 90 days of onset, and longer hospital stay ( P<0.05). In the EVT group, 11 patients (27.5%) had good prognosis and 29 patients (72.5%) had poor prognosis 90 days after onset. Compared with the good prognosis group, the poor prognosis group had significantly higher blood glucose level and lower Alberta Stroke Program Early CT Score (ASPECT) on admission ( P<0.05). Multivariate Logistic regression analysis showed that blood glucose on admission ( OR=2.363, 95% CI: 1.134-4.928, P=0.022) and ASPECT score on admission ( OR=0.273, 95% CI: 0.088-0.854, P=0.026) were independent influencing factors for poor prognosis in AIS patients after EVT. Conclusion:AIS patients aged ≥85 years received EVT have better prognosis compared with those accepted standard medical therapy; these patients with high glucose level and low ASPECT score on admission have poor prognosis.

Objective:To investigate immunotherapy effects and mechanism of BCG and recombinant BCG(rBCG)with c-di-AMP as adjuvant on melanoma in mice model.Methods:Melanoma mice model was established by B16F10 cell subcutaneous injec-tion in groin,and treated with 1×106 CFU of BCG and rBCG by adjacent injection of subcutaneous tumor for 3 times,respectively.Survival of melanotic mice,tumor growth and metastasis were observed.Tumor tissues of mice were isolated to prepare cell suspen-sion,and proportion of immune cells were detected by flow cytometry.Transcriptional levels of immune-related genes in tumor tissues were detected by qRT-PCR.Results:Both BCG and rBCG immunotherapy could significantly inhibit growth in melanoma mice and prolong survival time of mice.rBCG showed better inhibition on metastasis than BCG.Both strains significantly reduced proportion of M2-type macrophages and myeloid-derived suppressor cell associated with tumor growth and metastasis.Both two strains promoted infiltration of lymphocytes in tumor tissues,and rBCG significantly increased proportion of B cells in tumor.BCG immunotherapy upregulated transcription levels of metastasis-related cytokines,while rBCG therapy had no effects on transcriptions of these genes.Conclusion:Both BCG and rBCG have immunotherapeutic effects on melanotic mice,and rBCG with c-di-AMP as adjuvant shows better inhibition on tumor metastasis than BCG,which mechanism was related to regulation of immune response in tumor tissues.

Objective:To compare the efficacies of endovascular therapy (EVT) and standard medical therapy in acute ischemic stroke (AIS) patients aged ≥85 years, and analyze the independent influencing factors for poor prognosis of AIS patients after EVT.Methods:Sixty-nine AIS patients aged ≥85 years admitted to Department of Neurology, Xi'an Third Hospital from January 2018 to April 2024, including 40 accepted EVT and 28 accepted standard medicinal therapy, were enrolled. Modified Rankin scale (mRS) was used to evaluate the prognosis of the patients 90 days after onset. General data, prognosis and complications between the EVT group and standard medical therapy group were compared. General data, treatment processes and complications between patients with good prognosis and poor prognosis in the EVT group were compared. Multivariate Logistic regression was used to analyze the independent influencing factors for poor prognosis in AIS patients after EVT.Results:Compared with the standard medical therapy, the EVT group had significantly lower NIHSS score at discharge, greater improvement in NIHSS score (NIHSS score at admission-NIHSS score at discharge), lower mRS score 90 days after onset, higher good prognosis rate, lower mortality rate within 90 days of onset, and longer hospital stay ( P<0.05). In the EVT group, 11 patients (27.5%) had good prognosis and 29 patients (72.5%) had poor prognosis 90 days after onset. Compared with the good prognosis group, the poor prognosis group had significantly higher blood glucose level and lower Alberta Stroke Program Early CT Score (ASPECT) on admission ( P<0.05). Multivariate Logistic regression analysis showed that blood glucose on admission ( OR=2.363, 95% CI: 1.134-4.928, P=0.022) and ASPECT score on admission ( OR=0.273, 95% CI: 0.088-0.854, P=0.026) were independent influencing factors for poor prognosis in AIS patients after EVT. Conclusion:AIS patients aged ≥85 years received EVT have better prognosis compared with those accepted standard medical therapy; these patients with high glucose level and low ASPECT score on admission have poor prognosis.

The development of 5G remote robot-assisted gastrointestinal surgery is an important breakthrough in remote surgery in the field of four-level surgery. This paper will review the development history of 5G remote robot assisted gastrointestinal surgery, and share the Gansu province people′s hospital in 5G remote robot assisted gastrointestinal surgery about preoperative preparation, network and equipment connection,“3+2” Trocar layout, safety emergency treatment mechanism of exploratory experience, for 5G remote robot assisted gastrointestinal surgery, and the status and prospect of 5G remote robot assisted gastrointestinal surgery.

Objective:To explore whether the duration of oral estrogen treatment before progesterone application affects neonatal outcome in single frozen-thawed embryo transfer (FET) with artificial cycles.Methods:It was a retrospective cohort study. Patients who underwent in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), receiving single frozen blastocyst transfer with artificial cycle and delivering a single live birth in the Reproductive Center of the Third Affiliated Hospital of Zhengzhou University between January 2015 and December 2019 were included. All FET cycles were divided into four groups according to the estrogen treatment duration before progesterone application, ≤12 d ( n=306), 13-15 d ( n=620), 16-18 d ( n=471), and ≥19 d ( n=275). Primary outcome was the incidence of small for gestational age (SGA). Secondary outcomes were the incidence of preterm birth, low birth weight, macrosomia and large for gestational age (LGA). Results:A total of 1 672 single blastocyst transfer cycles were included. The incidence of SGA among the four groups was 7.8% (24/306), 4.8% (30/620), 5.7% (27/471), and 7.6% (21/275), respectively, with no statistically significant difference ( P=0.204). The results of multiple logistic regression analysis showed that the duration of estrogen used before progesterone application did not affect the incidence of SGA in singleton offspring (with ≤12 d as the reference, 13-15 d: a OR=1.37, 95% CI: 0.70-2.70, P=0.361; 16-18 d: a OR=0.74, 95% CI: 0.40-1.36, P=0.336; ≥19 d: a OR=0.81, 95% CI: 0.44-1.49, P=0.501). There were no significant differences in neonatal preterm birth rate ( P=0.204), low birth weight ( P=0.582), incidences of macrosomia ( P=0.201) and LGA infants ( P=0.335) among the four groups. Conclusion:In artificial FET cycle, the duration of oral estrogen treatment before progesterone application does not affect the outcome of singleton offspring after single blastocyst transfer.

Objective:To evaluate the cumulative live birth rate (CLBR) of mild stimulation and conventional stimulation in Poseidon 4 group for progestin-primed ovarian stimulation protocols (PPOS).Methods:It was a single-center, retrospective cohort study. The study included the first in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) cycles in the Reproductive Center of the Third Affiliated Hospital of Zhengzhou University from January 2017 to March 2020, and included patients met the criteria of Poseidon 4 group and accepted PPOS. According to the different starting dosage of gonadotropin (Gn), it was divided into mild stimulation group and conventional stimulation group. In mild stimulation group, Gn starting dosage was 150 U, and in conventional stimulation group Gn starting dosage was 300 U. The primary outcome measure was CLBR. Secondary observation indicators were No. of oocytes retrieved, No. of two pronuclei (2PN), No. of available embryos, No. of high-quality embryos and cumulative pregnancy rate. Results:A total of 1 334 cycles met the inclusion and exclusion criteria. After 1∶3 propensity score matching (PSM) model, 116 cycles of mild stimulation and 348 cycles of conventional stimulation were included for analysis. The total dosage of Gn used in the conventional ovarian stimulation group was significantly higher than that in the mild stimulation group [2 700.00 (2 400.00, 3 300.00) U vs. 1 500.00 (918.75, 2 456.25) U, P<0.001]. The number of oocytes retrieved [3.00 (2.00, 4.00)], 2PN [2.00 (1.00, 3.00)], available embryos [1.00 (1.00, 2.00)] and high-quality embryos [1.00 (0.00, 1.00)] in the conventional stimulation group were significantly higher than those in the mild stimulation group [2.00 (1.00, 3.00), P<0.001; 1.00 (1.00, 2.00), P=0.002; 1.00 (0.00,2.00), P=0.002; 0.00 (0.00, 1.00), P=0.025]. There was no statistical difference in the cumulative pregnancy rate between mild stimulation and conventional stimulation [15.52% (18/116) vs. 19.54% (68/348), P=0.334]. The CLBR of the mild stimulation group was 11.21% (13/116), and the CLBR of the conventional stimulation group was 14.08% (49/348), with no significant difference between the two groups ( P=0.431). Conclusion:Conventional stimulation increased the dosage of Gn used, and the number of oocytes retrieved and available embryos were more than those in mild stimulation, but the CLBR was similar between the two protocols. Therefore, mild stimulation is also an important clinical option for patients with low ovarian prognosis.

Objective:To compare the clinical outcomes of dydrogesterone and medroxyprogesterone acetate (MPA) in the progestin-primed ovarian stimulation (PPOS) protocol for patients with poor ovarian response (POR).Methods:This study was a single-center retrospective cohort study. POR patients who underwent PPOS protocol in Reproductive Center of the Third Affiliated Hospital of Zhengzhou University from January 2019 to September 2021 were included for analysis. According to different progestin drugs used, they were divided into dydrogesterone group and MPA group. Propensity score matching (PSM) was performed 1∶3 to correct for confounding factors. Outcome measures were the number of available embryos, oocytes retrieved, two pronuclei (2PN) and high-quality embryos, the clinical pregnancy rate and the continuing pregnancy rate in the first frozen embryo transfer cycle.Results:A total of 1 962 cycles were included, including 494 cycles in the dydrogesterone group and 1 468 cycles in the MPA group. There was a statistically significant difference in infertility factors between the two groups ( P=0.045). The other baseline characteristics were not significantly different (all P>0.05). The initiating dosage of gonadotropin (Gn) in the dydrogesterone group [300 (225, 300) U] was lower than that in the MPA group [300 (300, 300) U, P<0.001]. There were no significant differences in the duration and total dosage of Gn used, premature luteinizing hormone surge rate, the number of oocytes retrieved, the number of 2PN, the number of available embryos and the number of good-quality embryos between the two groups (all P>0.05). A total of 1 331 cycles underwent the first frozen-thawed embryo transfer, including 268 cycles in the dydrogesterone group and 1 063 cycles in the MPA group. There were no significant differences in endometrial thickness on the day of embryo transfer, the number of transferred embryos, the stage of transferred embryos, and the endometrial preparation protocols between the two groups (all P>0.05). There were no significant differences in the clinical pregnancy rate and the ongoing pregnancy rate between the two groups ( P=0.832, P=0.798). Conclusion:For POR patients, similar clinical outcomes were obtained with dydrogesterone and MPA in the PPOS protocol, suggesting that dydrogesterone can be an effective alternative to the PPOS protocol.